Table 2.
Follow‐up periods | Assessment | Group | Success | Failure | p Value |
---|---|---|---|---|---|
1 week | Clinical | MTA | 100% | 0% | ‐ |
Bioceramic | 100% | 0% | |||
Radiographic | MTA | 100% | 0% | ‐ | |
Bioceramic | 100% | 0% | |||
3 months | Clinical | MTA | 95% | 5% | 0.311 |
Bioceramic | 100% | 0% | |||
Radiographic | MTA | 95% | 5% | 0.311 | |
Bioceramic | 100% | 0% | |||
6 months | Clinical | MTA | 95% | 5% | 0.311 |
Bioceramic | 100% | 0% | |||
Radiographic | MTA | 95% | 5% | 0.311 | |
Bioceramic | 100% | 0% | |||
9 months | Clinical | MTA | 95% | 5% | 0.311 |
Bioceramic | 100% | 0% | |||
Radiographic | MTA | 95% | 5% | 0.311 | |
Bioceramic | 100% | 0% | |||
12 months | Clinical | MTA | 95% | 5% | 0.311 |
Bioceramic | 100% | 0% | |||
Radiographic | MTA | 95% | 5% | 0.311 | |
Bioceramic | 100% | 0% |
Abbreviation: MTA, Mineral Trioxide Aggregate.